Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease

By Malayandi Rajkumar   Kondamudi Phani   Ruby P.   Aggarwal Deepika  

Drug Delivery and Translational Research, Vol. 4, Iss. 2, 2014-04 ,pp. : 187-202

Springer Publishing Company

Access to resources Recommend Favorite

Colon Targeted Rifaximin Nanosuspension for the Treatment of Inflammatory Bowel Disease (IBD)

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 15, Iss. 2, 2016-12 ,pp. : 101-117

Bentham Science Publishers

Access to resources Recommend Favorite

Imaging of the Colon in Inflammatory Bowel Disease: Ready for Prime Time?

By  

Current Drug Targets, Vol. 13, Iss. 10, 2012-09 ,pp. : 1252-1260

Bentham Science Publishers

Access to resources Recommend Favorite

Design and Development of Novel Azo Prodrugs using Various Permutations and Combinations of 5- and 4-Aminosalicylic Acids for Inflammatory Bowel Disease: A Colon-Targeted Approach

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 12, Iss. 5, 2013-10 ,pp. : 328-340

Bentham Science Publishers

Access to resources Recommend Favorite

Specific changes of enteric mycobiota and virome in inflammatory bowel disease

By  

Journal of Digestive Diseases, Vol. 19, Iss. 1, 2018-01 ,pp. : 2-7

John Wiley & Sons Inc

Access to resources Recommend Favorite